Europe
Peptinnovate Ltd announces that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect. The new website for Immune Regulation is www.immuneregulation.com.
EIB financing strengthens F2G´s research and innovation
COMBINATION OF CUTTING-EDGE IPSC AND AI TECHNOLOGIES CREATES OPPORTUNITY TO DISCOVER NOVEL METABOLIC LIGANDS TO ACCELERATE DRUG DISCOVERY IN RARE METABOLIC DISEASES
Acacia Pharma Group plc announces that data and analyses from its positive Phase 3 clinical trial of BARHEMSYS™ have been published (Habib et al1) in the online edition of the leading peer-reviewed journal Anesthesiology, the official publication of the American Society of Anesthesiologists.
The prevalence of allergic diseases has increased significantly over the last decades, creating substantial financial and societal burdens. Due to this, researchers are trying to discover new approaches to the prevention and treatment of these diseases.
New therapeutic combination is expected to be generally applicable to many solid tumors with high unmet medical need
MorphoSys AG announced today that its licensee Janssen Research & Development, LLC (Janssen) initiated a phase 2 clinical study of guselkumab in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease also known as acne inversa.
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following investor conferences this week.
Toward the end of every year, biopharma executives are asked to dust off their crystal balls and predict what the next year might reveal. It’s that time of year again! Find out what execs are saying about M&A, gene therapy, sickle cell, and more.
Shares of Arsanis, Inc. stock are up more than 25 percent in premarket trading after the company announced that it will merge with privately-held X4 Pharmaceuticals, Inc. as part of a reverse merger that will provide X4 with a quick path to being traded on the Nasdaq.
PRESS RELEASES